•
Jun 30, 2022
Arrowhead Pharmaceuticals Q3 2022 Earnings Report
Reported fiscal 2022 third quarter results.
Key Takeaways
Arrowhead Pharmaceuticals reported a net loss of $72.05 million, or $0.68 per share, for the fiscal third quarter ended June 30, 2022. Revenue was $32.41 million.
Published results from a Phase 2 clinical study of fazirsiran (TAK-999/ARO-AAT) in the New England Journal of Medicine (NEJM).
Hosted a pulmonary research & development (R&D) Day in New York City.
Initiated Phase 1/2a clinical studies for ARO-MUC5AC and ARO-RAGE.
Initiated the Phase 2 GATEWAY clinical study of ARO-ANG3.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
Forward Guidance
No forward guidance provided in the press release.